Actively Recruiting
Study of Obinutuzumab to Induce Remission in Adults with Relapsing PR3-ANCA Granulomatosis with Polyangiitis Phase 2 Open-label
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-03-06
33
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Granulomatosis with polyangiitis is a serious inflammatory disease affecting blood vessels, often associated with anti-neutrophil cytoplasmic antibodies ANCA. This research focuses on patients with relapsing PR3-ANCA granulomatosis with polyangiitis, studying the effects of obinutuzumab on inducing clinical and serological remission. The study aims to improve long-term remission rates and reduce relapse risks compared to current treatments like rituximab, based on previous trial results that showed limitations in relapse prevention. Participants will receive obinutuzumab through intravenous infusions at weeks 0, 2, 24, and 26. Alongside this, a standardized glucocorticoid tapering schedule will be followed, with premedications including methylprednisolone, paracetamol, and dexchlorpheniramine to help prevent infusion reactions. This is a single-arm, open-label phase 2 study evaluating obinutuzumab for remission induction. During the study, participants will be monitored for remission status at week 24, including clinical and serological measures. Safety will be assessed by tracking adverse events and relapses up to week 52. Additional evaluations include quality of life questionnaires, vasculitis damage index, and immune cell monitoring for B-cell repopulation. The total study duration includes treatment and follow-up assessments to evaluate efficacy and safety over one year.
CONDITIONS
Brief Title
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
Research Team
B
Benjamin TERRIER, PhD
K
Karima MESBAHI-IHADJADENE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here